Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab. (Record no. 28263732)

MARC details
000 -LEADER
fixed length control field 01602 a2200445 4500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250517211123.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 201810s 0 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 2211-0356
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1016/j.msard.2018.03.021
Source of number or code doi
040 ## - CATALOGING SOURCE
Original cataloging agency NLM
Language of cataloging eng
Transcribing agency NLM
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Hümmert, Martin W
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Date of production, publication, distribution, manufacture, or copyright notice 20181011
245 00 - TITLE STATEMENT
Title Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab.
Medium [electronic resource]
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. Multiple sclerosis and related disorders
Date of publication, distribution, etc. May 2018
300 ## - PHYSICAL DESCRIPTION
Extent 87-89 p.
Other physical details digital
500 ## - GENERAL NOTE
General note Publication Type: Case Reports; Journal Article
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Adult
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Alemtuzumab
General subdivision therapeutic use
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antibodies, Monoclonal, Humanized
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Brain Stem
General subdivision diagnostic imaging
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Daclizumab
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Drug Substitution
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Female
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Immunoglobulin G
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Immunologic Factors
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Inflammation
General subdivision etiology
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Multiple Sclerosis
General subdivision diagnostic imaging
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Natalizumab
General subdivision adverse effects
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Deppe, Julian
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Pul, Refik
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Wurster, Ulrich
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Schwenkenbecher, Philipp
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Sühs, Kurt-Wolfram
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Bronzlik, Paul
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Stangel, Martin
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Skripuletz, Thomas
773 0# - HOST ITEM ENTRY
Title Multiple sclerosis and related disorders
Related parts vol. 22
-- p. 87-89
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://doi.org/10.1016/j.msard.2018.03.021">https://doi.org/10.1016/j.msard.2018.03.021</a>
Public note Available from publisher's website

No items available.